Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
2026 · 1st Quarter (Jan 1 - Mar 31)
MERCK & CO., INC.
Filed by CROSSROADS STRATEGIES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- CROSSROADS STRATEGIES, LLC
- Client
- MERCK & CO., INC.
- Filing UUID
- 271f4e33-4030-44c9-b57f-47b92f3c25c7
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Literal federal measure citations: S.891
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to tax reform; R&D tax credit; international taxation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Literal federal measure citations: H.R.1
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.